<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35091341</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Immune response to a conserved enteroviral epitope of the major capsid VP1 protein is associated with lower risk of cardiovascular disease.</ArticleTitle><Pagination><StartPage>103835</StartPage><MedlinePgn>103835</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">103835</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2022.103835</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(22)00019-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Major cardiac events including myocardial infarction (MI) are associated with viral infections. However, how specific infections contribute to the cardiovascular insults has remained largely unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We employed next generation phage display mimotope-variation analysis (MVA) to explore the link between antibody-based immune response and severe cardiovascular conditions. Here, we used a case-control design, including the first-stage discovery cohort (n = 100), along with cohorts for second-stage discovery (n = 329) and validation (n = 466).</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We observed strong antibody response to the peptide antigens with Gly-Ile-X-Asp (G-I-X-D) core structure in healthy individuals but not in patients with MI. Analysis of the origin of this epitope linked it with the N-terminus of the VP1 protein of poliovirus 3 (PV3), but also other species of picornaviruses. Consistently, we found low levels of antibody response to the G-I-X-D epitope in individuals with severe cardiac disease complications.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our findings imply that antibody response to the G-I-X-D epitope is associated with polio vaccinations and that high antibody levels to this epitope could discriminate healthy individuals from prospective MI patients as a blood-derived biomarker. Together, these findings highlight the importance of epitope-specific antibody response and suggest that protective immunity against the polio- and non-polio enteroviral infections support improved cardiovascular health.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Estonian Ministry of Education (5.1-4/20/170), Estonian Research Council (PRG573, PRG805), H2020-MSCA-RISE-2016 (EU734791), H2020 PANBioRA (EU760921), European Union through the European Regional Development Fund (Project no. 2014-2020.4.01.15-0012), Helsinki University Hospital grants, Mary and Georg C. Ehrnrooth Foundation, Finnish Eye Foundation, Finska Läkaresällskapet, The Finnish Society of Sciences and Letters, Magnus Ehrnrooth Foundation and Sigrid Jusélius Foundation.</AbstractText><CopyrightInformation>Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pupina</LastName><ForeName>Nadežda</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Protobios LLC, Mäealuse 4, Tallinn 12618, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avarlaid</LastName><ForeName>Annela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biotechnology, Tallinn University of Technology, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadam</LastName><ForeName>Helle</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Protobios LLC, Mäealuse 4, Tallinn 12618, Estonia; Department of Chemistry and Biotechnology, Tallinn University of Technology, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pihlak</LastName><ForeName>Arno</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Protobios LLC, Mäealuse 4, Tallinn 12618, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaago</LastName><ForeName>Mariliis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Protobios LLC, Mäealuse 4, Tallinn 12618, Estonia; Department of Chemistry and Biotechnology, Tallinn University of Technology, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuvikene</LastName><ForeName>Jürgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Protobios LLC, Mäealuse 4, Tallinn 12618, Estonia; Department of Chemistry and Biotechnology, Tallinn University of Technology, Estonia; dxlabs LLC, Mäealuse 4, Tallinn 12618, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rähni</LastName><ForeName>Annika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Protobios LLC, Mäealuse 4, Tallinn 12618, Estonia; Department of Chemistry and Biotechnology, Tallinn University of Technology, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Planken</LastName><ForeName>Anu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The North Estonia Medical Center, Tallinn, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Planken</LastName><ForeName>Margus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The North Estonia Medical Center, Tallinn, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalso</LastName><ForeName>Eija</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki University Hospital and Department of Pharmacology and SleepWell Research Programme, University of Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tienari</LastName><ForeName>Pentti J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neurocenter, Helsinki University Hospital, and Translational Immunology Research Program, University of Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieminen</LastName><ForeName>Janne K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neurocenter, Helsinki University Hospital, and Translational Immunology Research Program, University of Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seppänen</LastName><ForeName>Mikko R J</ForeName><Initials>MRJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neurocenter, Helsinki University Hospital, and Translational Immunology Research Program, University of Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaheri</LastName><ForeName>Antti</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Virology, Medicum, University of Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindholm</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Finland; Minerva Foundation Institute for Medical Research, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinisalo</LastName><ForeName>Juha</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pussinen</LastName><ForeName>Pirkko</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timmusk</LastName><ForeName>Tõnis</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Protobios LLC, Mäealuse 4, Tallinn 12618, Estonia; Department of Chemistry and Biotechnology, Tallinn University of Technology, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palm</LastName><ForeName>Kaia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Protobios LLC, Mäealuse 4, Tallinn 12618, Estonia; Department of Chemistry and Biotechnology, Tallinn University of Technology, Estonia. Electronic address: kaia@protobios.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002213" MajorTopicYN="N">Capsid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibodies</Keyword><Keyword MajorTopicYN="N">Cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">Enteroviruses</Keyword><Keyword MajorTopicYN="N">Epitope</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Poliovirus</Keyword></KeywordList><CoiStatement>Declaration of interests AP (Arno Pihlak) and KP are inventors of the patent application (PCT Application No. US/14,079,626) filed by Protobios that covers the use of phage display method for manipulating and monitoring humoral immunity. NP, HS, AP (Arno Pihlak), MJ, JT, AR, TT, and KP are affiliated with Protobios Llc. JS reported payment/honoraria from Astra- Zeneca, Amgen, Abbott and Bayer. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>29</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35091341</ArticleId><ArticleId IdType="pmc">PMC8801986</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2022.103835</ArticleId><ArticleId IdType="pii">S2352-3964(22)00019-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roth G.A., Mensah G.A., CO Johnson, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755038</ArticleId><ArticleId IdType="pubmed">33309175</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmis A. European heart journal - quality of care &amp; clinical outcomes: becoming the go-to journal for cardiovascular outcomes research worldwide. Eur Heart J. 2019;40(46):3753.</Citation><ArticleIdList><ArticleId IdType="pubmed">31811723</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalak M., Agellon L.B. Stress coping strategies in the heart: an integrated view. Front Cardiovasc Med. 2018;5:168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6258784</ArticleId><ArticleId IdType="pubmed">30519562</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox K.A.A., Metra M., Morais J., Atar D. The myth of ‘stable’ coronary artery disease. Nat Rev Cardiol. 2020;17(1):9–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">31358978</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.</Citation><ArticleIdList><ArticleId IdType="pubmed">15843671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138(5 Pt 2):S419–S420.</Citation><ArticleIdList><ArticleId IdType="pubmed">10539839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld M.E., Campbell L.A. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost. 2011;106(5):858–867.</Citation><ArticleIdList><ArticleId IdType="pubmed">22012133</ArticleId></ArticleIdList></Reference><Reference><Citation>Murillo H., Restrepo C.S., Marmol-Velez J.A., et al. Infectious diseases of the heart: pathophysiology, clinical and imaging overview. Radiographics. 2016;36(4):963–983.</Citation><ArticleIdList><ArticleId IdType="pubmed">27399236</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato K., Sinclair J.E., Sadeghirad H., Fraser J.F., Short K.R., Kulasinghe A. Cardiovascular disease in SARS-CoV-2 infection. Clin Transl Immunol. 2021;10(9):e1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423130</ArticleId><ArticleId IdType="pubmed">34512975</ArticleId></ArticleIdList></Reference><Reference><Citation>Szwed P., Gasecka A., Zawadka M., et al. Infections as novel risk factors of atherosclerotic cardiovascular diseases: pathophysiological links and therapeutic implications. J Clin Med. 2021;10(12):2539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8229654</ArticleId><ArticleId IdType="pubmed">34201137</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra S., Drautz-Moses D.I., Alhede M., et al. In silico analyses of metagenomes from human atherosclerotic plaque samples. Microbiome. 2015;3:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4559171</ArticleId><ArticleId IdType="pubmed">26334731</ArticleId></ArticleIdList></Reference><Reference><Citation>Pothineni N.V.K., Subramany S., Kuriakose K., et al. Infections, atherosclerosis, and coronary heart disease. Eur Heart J. 2017;38(43):3195–3201.</Citation><ArticleIdList><ArticleId IdType="pubmed">29020241</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P., Mendall M.A., Carrington D., et al. Association of helicobacter pylori and chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ. 1995;311(7007):711–714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2550716</ArticleId><ArticleId IdType="pubmed">7549683</ArticleId></ArticleIdList></Reference><Reference><Citation>Pussinen P.J., Jousilahti P., Alfthan G., Palosuo T., Asikainen S., Salomaa V. Antibodies to periodontal pathogens are associated with coronary heart disease. Arterioscler Thromb Vasc Biol. 2003;23(7):1250–1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714435</ArticleId></ArticleIdList></Reference><Reference><Citation>Reunanen A., Roivainen M., Kleemola M., et al. Enterovirus, mycoplasma and other infections as predictors for myocardial infarction. J Intern Med. 2002;252(5):421–429.</Citation><ArticleIdList><ArticleId IdType="pubmed">12528760</ArticleId></ArticleIdList></Reference><Reference><Citation>Roivainen M., Viik-Kajander M., Palosuo T., et al. Infections, inflammation, and the risk of coronary heart disease. Circulation. 2000;101(3):252–257.</Citation><ArticleIdList><ArticleId IdType="pubmed">10645920</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinola-Klein C., Rupprecht H.J., Blankenberg S., et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke. 2002;33(11):2581–2586.</Citation><ArticleIdList><ArticleId IdType="pubmed">12411646</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupprecht H.J., Blankenberg S., Bickel C., et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation. 2001;104(1):25–31.</Citation><ArticleIdList><ArticleId IdType="pubmed">11435333</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Quyyumi A.A., Norman J.E., et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol. 2000;85(2):140–146.</Citation><ArticleIdList><ArticleId IdType="pubmed">10955367</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesonen E., Andsberg E., Ohlin H., et al. Dual role of infections as risk factors for coronary heart disease. Atherosclerosis. 2007;192(2):370–375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16780845</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgner D.P., Sabin M.A., Magnussen C.G., et al. Early childhood hospitalisation with infection and subclinical atherosclerosis in adulthood: the Cardiovascular Risk in Young Finns Study. Atherosclerosis. 2015;239(2):496–502.</Citation><ArticleIdList><ArticleId IdType="pubmed">25721701</ArticleId></ArticleIdList></Reference><Reference><Citation>Pussinen P.J., Paju S., Koponen J., et al. Association of childhood oral infections with cardiovascular risk factors and subclinical atherosclerosis in adulthood. JAMA Netw Open. 2019;2(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487573</ArticleId><ArticleId IdType="pubmed">31026022</ArticleId></ArticleIdList></Reference><Reference><Citation>Soehnlein O., Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20(8):589–610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112476</ArticleId><ArticleId IdType="pubmed">33976384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson J.S. Multiple infectious agents and the origins of atherosclerotic coronary artery disease. Front Cardiovasc Med. 2016;3:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018484</ArticleId><ArticleId IdType="pubmed">27672638</ArticleId></ArticleIdList></Reference><Reference><Citation>Musher D.M., Abers M.S., Corrales-Medina V.F. Acute infection and myocardial infarction. N Engl J Med. 2019;380(2):171–176.</Citation><ArticleIdList><ArticleId IdType="pubmed">30625066</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren-Gash C., Blackburn R., Whitaker H., McMenamin J., Hayward A.C. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018;51(3):1701794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5898931</ArticleId><ArticleId IdType="pubmed">29563170</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov M.P. Some results of the work on mass immunization in the Soviet Union with live poliovirus vaccine prepared from Sabin strains. Bull World Health Organ. 1961;25:79–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2555546</ArticleId><ArticleId IdType="pubmed">13879389</ArticleId></ArticleIdList></Reference><Reference><Citation>Horstmann D.M. The Sabin live poliovirus vaccination trials in the USSR, 1959. Yale J Biol Med. 1991;64(5):499–512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2589490</ArticleId><ArticleId IdType="pubmed">1814062</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaara S., Nieminen M.S., Lokki M.L., et al. Cohort profile: the Corogene study. Int J Epidemiol. 2012;41(5):1265–1271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465766</ArticleId><ArticleId IdType="pubmed">21642350</ArticleId></ArticleIdList></Reference><Reference><Citation>Liljestrand J.M., Paju S., Pietiainen M., et al. Immunologic burden links periodontitis to acute coronary syndrome. Atherosclerosis. 2018;268:177–184.</Citation><ArticleIdList><ArticleId IdType="pubmed">29232563</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustonen L., Aho T., Harno H., Sipila R., Meretoja T., Kalso E. What makes surgical nerve injury painful? A 4-year to 9-year follow-up of patients with intercostobrachial nerve resection in women treated for breast cancer. Pain. 2019;160(1):246–256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6319585</ArticleId><ArticleId IdType="pubmed">30234699</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadam H., Pihlak A., Jaago M., et al. Identification of two highly antigenic epitope markers predicting multiple sclerosis in optic neuritis patients. EBioMedicine. 2021;64</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7841498</ArticleId><ArticleId IdType="pubmed">33493797</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadam H., Pihlak A., Kivil A., et al. Prostaglandin D2 receptor DP1 antibodies predict vaccine-induced and spontaneous narcolepsy type 1: large-scale study of antibody profiling. EBioMedicine. 2018;29:47–59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5925455</ArticleId><ArticleId IdType="pubmed">29449194</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolde R. pheatmap: Pretty Heatmaps [Internet]. 2019 [cited 2021 Apr 21]. Available from: https://CRAN.R-project.org/package=pheatmap</Citation></Reference><Reference><Citation>Kruup M. Finding motifs from short peptides [Internet]. 2013 [cited 2021 Jun 11]. Available from: https://comserv.cs.ut.ee/home/files/Mari-Liis+Kruup+-+Finding+motifs+from+short+peptides.pdf?study=ATILoputoo&amp;reference=C2F24DE244D358C55E32D7A221FEE5CB523D4E9C</Citation></Reference><Reference><Citation>Kassambara A. ggpubr: “ggplot2” Based Publication Ready Plots [Internet]. 2020 [cited 2021 Apr 21]. Available from: https://CRAN.R-project.org/package=ggpubr</Citation></Reference><Reference><Citation>Madden T. BLAST+ features. BLAST® Command Line Applications User Manual. National Center for Biotechnology Information (US) [Internet]. 2020 [cited 2021 Oct 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK569839/</Citation></Reference><Reference><Citation>Krithe JH. Rtsne: t-distributed stochastic neighbor embedding using a Barnes-Hut implementation [Internet]. 2015 [cited 2021 Apr 21]. Available from: https://github.com/jkrijthe/Rtsne</Citation></Reference><Reference><Citation>Wickham H., Averick M., Bryan J., Chang W., McGowan L. Welcome to the tidyverse. J Open Source Softw. 2019;4:43.</Citation></Reference><Reference><Citation>Graham S., Wang E.C., Jenkins O., Borysiewicz L.K. Analysis of the human T-cell response to picornaviruses: identification of T-cell epitopes close to B-cell epitopes in poliovirus. J Virol. 1993;67(3):1627–1637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237534</ArticleId><ArticleId IdType="pubmed">7679749</ArticleId></ArticleIdList></Reference><Reference><Citation>Roivainen M., Piirainen L., Rysa T., Narvanen A., Hovi T. An immunodominant N-terminal region of VP1 protein of poliovirion that is buried in crystal structure can be exposed in solution. Virology. 1993;195(2):762–765.</Citation><ArticleIdList><ArticleId IdType="pubmed">8393243</ArticleId></ArticleIdList></Reference><Reference><Citation>Harb J., Mennesson N., Lepetit C., et al. Comparison of monoclonal gammopathies linked to poliovirus or coxsackievirus vs. other infectious pathogens. Cells. 2021;10(2):438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7922508</ArticleId><ArticleId IdType="pubmed">33669483</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanink C.M., Veenstra L., Poort Y.A., Kaan J.A., Galama J.M. Coxsackievirus B1-based antibody-capture enzyme-linked immunosorbent assay for detection of immunoglobulin G (IgG), IgM, and IgA with broad specificity for enteroviruses. J Clin Microbiol. 1993;31(12):3240–3246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC266387</ArticleId><ArticleId IdType="pubmed">8308117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukashev A.N., Vakulenko Y.A. Molecular evolution of types in non-polio enteroviruses. J Gen Virol. 2017;98(12):2968–2981.</Citation><ArticleIdList><ArticleId IdType="pubmed">29095688</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D.M., Zhang Y., Scheuermann R.H. Epidemiology and sequence-based evolutionary analysis of circulating non-polio enteroviruses. Microorganisms. 2020;8(12):E1856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7759938</ArticleId><ArticleId IdType="pubmed">33255654</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer L., van der Sanden S.M.G., Calis J.C.J., et al. High frequency of polio-like enterovirus C strains with differential clustering of CVA-13 and EV-C99 subgenotypes in a cohort of Malawian children. Arch Virol. 2018;163(10):2645–2653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132918</ArticleId><ArticleId IdType="pubmed">29808442</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamadpoor T., Nabavinia M., Gholoobi A., Alavi M., Meshkat Z. Enteroviruses in acute myocardial infarction. Iran J Public Health. 2012;41(8):71–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3469030</ArticleId><ArticleId IdType="pubmed">23113227</ArticleId></ArticleIdList></Reference><Reference><Citation>Roger V.L. Epidemiology of myocardial infarction. Med Clin N Am. 2007;91(4):537–552. ix.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2537993</ArticleId><ArticleId IdType="pubmed">17640535</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S.Y., Kim K.S., Lee Y.S., et al. Identification of enteroviruses by using monoclonal antibodies against a putative common epitope. J Clin Microbiol. 2003;41(7):3028–3034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165318</ArticleId><ArticleId IdType="pubmed">12843038</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Zhu L., Fan J., et al. Rules governing genetic exchanges among viral types from different enterovirus a clusters. J Gen Virol. 2020;101(11):1145–1155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7879560</ArticleId><ArticleId IdType="pubmed">32762804</ArticleId></ArticleIdList></Reference><Reference><Citation>Agol V.I. Molecular mechanisms of poliovirus variation and evolution. Curr Top Microbiol Immunol. 2006;299:211–259.</Citation><ArticleIdList><ArticleId IdType="pubmed">16568901</ArticleId></ArticleIdList></Reference><Reference><Citation>Agol V.I. Vaccine-derived polioviruses. Biologicals. 2006;34(2):103–108.</Citation><ArticleIdList><ArticleId IdType="pubmed">16650771</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens R.J., Pallansch M.A., Chumakov K.M., et al. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal. 2013;33(4):606–646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7890644</ArticleId><ArticleId IdType="pubmed">23550968</ArticleId></ArticleIdList></Reference><Reference><Citation>Famulare M., Selinger C., McCarthy K.A., Eckhoff P.A., Chabot-Couture G. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine. PLOS Biol. 2018;16(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942853</ArticleId><ArticleId IdType="pubmed">29702638</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins H.E., Aylward R.B., Gasasira A., et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med. 2010;362(25):2360–2369.</Citation><ArticleIdList><ArticleId IdType="pubmed">20573924</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Garcia M.D., Kebe O., Fall A.D., Ndiaye K. Identification and molecular characterization of non-polio enteroviruses from children with acute flaccid paralysis in West Africa, 2013-2014. Sci Rep. 2017;7(1):3808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5476622</ArticleId><ArticleId IdType="pubmed">28630462</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouin A., Gretteau P.A., Wehbe M., et al. Enterovirus persistence in cardiac cells of patients with idiopathic dilated cardiomyopathy is linked to 5′ terminal genomic RNA-deleted viral populations with viral-encoded proteinase activities. Circulation. 2019;139(20):2326–2338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6517084</ArticleId><ArticleId IdType="pubmed">30755025</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennert R., Crijns H.J., Heymans S. Acute viral myocarditis. Eur Heart J. 2008;29(17):2073–2082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2519249</ArticleId><ArticleId IdType="pubmed">18617482</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlton K.U. Dilated cardiomyopathy. Circulation. 2019;139(20):2339–2341.</Citation><ArticleIdList><ArticleId IdType="pubmed">31082299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilton T., Dunn G., Eastwood D., Minor P.D., Martin J. Effect of formaldehyde inactivation on poliovirus. J Virol. 2014;88(20):11955–11964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4178759</ArticleId><ArticleId IdType="pubmed">25100844</ArticleId></ArticleIdList></Reference><Reference><Citation>Herremans T., Reimerink J.H., Kimman T.G., van Der Avoort H.G., Koopmans M.P. Antibody responses to antigenic sites 1 and 3 of serotype 3 poliovirus after vaccination with oral live attenuated or inactivated poliovirus vaccine and after natural exposure. Clin Diagn Lab Immunol. 2000;7(1):40–44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC95819</ArticleId><ArticleId IdType="pubmed">10618274</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah P.N.M., Filman D.J., Karunatilaka K.S., et al. Cryo-EM structures reveal two distinct conformational states in a picornavirus cell entry intermediate. PLOS Pathog. 2020;16(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7549760</ArticleId><ArticleId IdType="pubmed">32997730</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschope C., Ammirati E., Bozkurt B., et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18(3):169–193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7548534</ArticleId><ArticleId IdType="pubmed">33046850</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Clavero M.A., Escribano-Romero E., Douglas A.J., Ley V. The N-terminal region of the VP1 protein of swine vesicular disease virus contains a neutralization site that arises upon cell attachment and is involved in viral entry. J Virol. 2001;75(2):1044–1047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114001</ArticleId><ArticleId IdType="pubmed">11134318</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X., Xie Z. Protein structure, neighbor effect, and a new index of amino acid dissimilarities. Mol Biol Evol. 2002;19(1):58–67.</Citation><ArticleIdList><ArticleId IdType="pubmed">11752190</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw J., Jorba J., Zhao K., et al. Dynamics of evolution of poliovirus neutralizing antigenic sites and other capsid functional domains during a large and prolonged outbreak. J Virol. 2018;92(9):e01949–17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899205</ArticleId><ArticleId IdType="pubmed">29444940</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell L.A., Rosenfeld M.E. Infection and atherosclerosis development. Arch Med Res. 2015;46(5):339–350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4524506</ArticleId><ArticleId IdType="pubmed">26004263</ArticleId></ArticleIdList></Reference><Reference><Citation>Musher D.M., Abers M.S., Corrales-Medina V.F. Acute infection and myocardial infarction. N Engl J Med. 2019;380(15):e21. Reply.</Citation><ArticleIdList><ArticleId IdType="pubmed">30625066</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin V., Voronel V.L., Timoshina M.A., Zaripova Z.A., Murina E.A., Khromov-Borisov N.N. Enterovirus infection as a risk factor of acute coronary syndrome and its complications. Klin Med (Mosk) 2011;89(2):25–29.</Citation><ArticleIdList><ArticleId IdType="pubmed">21574437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilback N.G., Mohammed A., Fohlman J., Friman G. Cardiovascular lipid accumulation with Coxsackie B virus infection in mice. Am J Pathol. 1990;136(1):159–167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877460</ArticleId><ArticleId IdType="pubmed">2153346</ArticleId></ArticleIdList></Reference><Reference><Citation>Koren O., Spor A., Felin J., et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4592–4598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063583</ArticleId><ArticleId IdType="pubmed">20937873</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuss S.K., Best G.T., Etheredge C.A., et al. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science. 2011;334(6053):249–252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3222156</ArticleId><ArticleId IdType="pubmed">21998395</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>